2,354 material Form 8-K filings that 2,004 companies we cover made with the SEC in November 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 1,081 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Datavault AI's board appointed Brett Moyer as Chief Executive Officer and President, effective immediately, after Nathaniel Bradley was removed from that role on November 1, 2026. Board changes also name Kimberly Briskey Chair and Teresa Gallo Chief Operating Officer, a shake-up that bears on how the company is run and governed.
Brett Moyer, previously CFO and a director, named CEO and President effective November 6, 2026; Nathaniel Bradley removed as CEO on November 1, 2026
Stanley Mbugua, previously Chief Accounting Officer, named Chief Financial Officer; Teresa Gallo named Chief Operating Officer
Kimberly Briskey named Chair of the Board; Christopher R. Hardt named Chair of the Audit Committee
Company says it will report third-quarter 2026 results on a date to be announced
Hyperscale Data entered a note purchase agreement dated November 6, 2026 with an institutional investor for convertible notes with an aggregate face amount of $27,027,027.03, including original issue discount. The first note closed the same day, and the notes convert into Class A common stock at a discount to market price, which could dilute existing shareholders.
Initial note: $10,810,810.81 principal for a $10,000,000 purchase price, closed November 6, 2026
Second note: $5,405,405.41 principal for a $5,000,000 purchase price, expected on or around November 16, 2026
Conversion at the lower of $0.30 or a 10% discount to the lowest 5-day VWAP, with a $0.1025 floor; issuance capped at 19.99% of outstanding shares unless stockholders approve
Notes accrue 8% interest and mature February 5, 2027, extending to May 5, 2027 after stockholder approval
EVgo reported third quarter 2026 results, with total revenue down 1% year-over-year while charging network revenue rose 29%. The net loss widened to $49.2 million, and the company updated its full-year 2026 guidance. The board also received a non-binding, unsolicited proposal from LS Power to acquire the shares it does not own for $2.00 per share in cash, which could affect shareholders if pursued.
Total Q3 2026 revenue was $91.4 million, down 1% from $92.3 million, while charging network revenue rose 29% to $71.8 million.
Q3 2026 net loss was $49.2 million, compared with $28.4 million in Q3 2025; adjusted EBITDA loss narrowed to $3.5 million from $5.0 million.
Updated 2026 guidance: total revenue of $375 million to $400 million and adjusted EBITDA loss of $15 million to $30 million.
On November 2, LS Power Equity Advisors proposed to acquire EVgo's Class A shares not already owned by LS Power for $2.00 per share in cash; a special committee of independent directors is reviewing it.
Randolph C. Read resigned from the board of Roman DBDR Acquisition Corp. II, along with its audit and compensation committees, effective immediately, on November 4, 2026. The filing states his resignation was not due to any disagreement with the company on operations, policies or practices, and the board named Bryn Sherman and Hunter Gary to fill the committee vacancies.
Randolph C. Read resigned from the board, audit committee and compensation committee on November 4, 2026, effective immediately
Bryn Sherman appointed chairperson of the Compensation Committee, effective November 4, 2026
Hunter Gary appointed as a member of the Audit Committee, effective November 4, 2026
Filing states the resignation was not the result of any disagreement with the company
Pono Capital Four and Blackstar Orbital Technologies signed a First Amendment to their Merger Agreement on November 5, 2026. The amendment lowers the Base Purchase Price used to set the Parent Shares paid to Blackstar securityholders, increases the equity plan share reserve, and extends the outside closing date. The filing says the rest of the Merger Agreement is unchanged, and the Business Combination still requires Pono shareholder approval.
Base Purchase Price reduced from $380,000,000 to $200,000,000, which sets the number of Parent Shares paid to Blackstar securityholders
Parent Shares reserved under the Equity Incentive Plan at Closing increased from 6,000,000 to 7,400,000
Company Outside Closing Date extended from March 31, 2027 to June 30, 2027
TEN Holdings reported third-quarter 2026 revenue of $640,000, up 17.9% from a year earlier, but its net loss rose 87.9% to $3,734,000. The loss reflects a $1.8 million write-off of previously capitalized service contracts and about $0.5 million in legal expenses, which the company calls non-recurring. Shareholders also face a change in finance leadership, as Ian M. Lawson became interim chief financial officer effective September 30, 2026.
Revenue was $640,000 versus $543,000 a year earlier; gross margin fell to 59.2% from 74.6%.
Net loss was $3,734,000, or $(0.31) per share, compared with $1,987,000, or $(0.84) per share, in the third quarter of 2025.
The company cited a $1.8 million write-off of capitalized service contracts and about $0.5 million in legal expenses.
Ian M. Lawson was appointed interim chief financial officer, effective September 30, 2026.
bioAffinity Technologies reported third-quarter 2026 revenue of approximately $1.1 million, down from approximately $1.4 million a year earlier, which it attributed to lower reimbursement per CyPath Lung test and a slight decline in cases at its Precision Pathology Laboratory Services subsidiary. The net loss widened to approximately $5.3 million from $5.1 million, as the operating loss grew to approximately $3.5 million from $2.3 million, and cash fell to approximately $2.6 million at September 30, 2026, which matters to shareholders given the company's continuing losses.
Q3 2026 revenue was approximately $1.1 million versus approximately $1.4 million in Q3 2025; nine-month CyPath Lung testing revenue rose 79% to approximately $1.1 million.
Q3 net loss was approximately $5.3 million versus $5.1 million; loss from operations was approximately $3.5 million versus $2.3 million.
Cash and cash equivalents were approximately $2.6 million at September 30, 2026, down from $6.4 million at December 31, 2025; a financing after quarter-end generated approximately $4.0 million in gross proceeds.
Rallybio said the closing of its merger with Avenzo Therapeutics, previously expected on November 6, 2026, has been postponed because certain conditions tied to listing the company's shares after the deal have not been met. The company did not deposit funds for a previously announced cash distribution with Computershare on November 5, 2026, so the payment and ex-dividend dates may be delayed.
Merger closing with Avenzo Therapeutics postponed from the expected November 6, 2026 date while listing approvals are sought
Funds for the cash distribution were not deposited with Computershare on November 5, 2026
Previously announced payment date and ex-dividend date for the cash distribution may be delayed; no new dates given
Sidus Space's audit committee concluded that its audited 2024 and 2025 annual reports and its 2026 quarterly reports for March 31 and June 30 should no longer be relied upon. The company expects the restatements to increase net loss for 2024 and for the first half of 2026, decrease net loss for 2025, and reduce stockholders' equity in every affected period, and it expects to report material weaknesses in internal controls.
Restatement covers the 2024 and 2025 annual reports and the Q1 and Q2 2026 quarterly reports; the 2024 and 2025 10-Ks were filed March 31, 2025 and April 1, 2026.
Net loss expected to increase by about $12.5 million for 2024 and about $4.1 million for the six months ended June 30, 2026; net loss expected to decrease by about $5.5 million for 2025.
Total stockholders' equity expected to decrease by about $15.0 million as of June 30, 2026, compared with amounts originally reported.
Main cause is warrant classification: 3,409,946 warrants issued December 17, 2024 should have been recorded as liabilities; the company also cited a $4.0 million impairment on its LS-2 satellite.
Mount Logan Capital appointed Brandon Harper as its Chief Accounting Officer and principal accounting officer, effective November 3, 2026. Brandon Satoren, the company's CFO, no longer serves as principal accounting officer, though he remains CFO.
Brandon Harper, age 33, appointed by the board on November 3, 2026, previously served as Group Controller from July 2026.
Harper received 7,080 restricted stock units on November 6, 2026, vesting in three equal installments on January 1, 2027, 2028 and 2029.
Brandon Satoren, Chief Financial Officer, no longer serves as principal accounting officer as of November 3, 2026.
The filing notes potential conflicts of interest with BC Partners Advisors L.P., the company's servicing agent and holder of a minority equity interest through an affiliate.
T3 Defense Inc. completed its acquisition of KeepZone AI Inc. on November 4, 2026, paying by issuing 425,594 shares of common stock to the seller, Nexera Technologies Ltd. An amendment to the purchase agreement raised the purchase price to $1,539,800 and lifted the seller's beneficial ownership limit in the company to 9.9%. The company said the deal was not a significant acquisition, so separate KeepZone financial statements are not required.
Purchase price raised to $1,539,800 under the amendment dated November 4, 2026
425,594 new common shares issued to Nexera Technologies Ltd. as consideration
Seller's beneficial ownership limit in T3 Defense raised to 9.9%
Company states the acquisition was not significant under Item 2.01 of Form 8-K
Knightscope received a Nasdaq deficiency letter on November 4, 2026, because its Class A Common Stock closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until May 3, 2027 to regain compliance, and the notice has no immediate effect on its listing, which continues under the symbol KSCP.
Nasdaq deficiency letter received November 4, 2026 for closing below $1.00 minimum bid price for 30 consecutive business days
Compliance Date is May 3, 2027, a 180 calendar day compliance period
Regaining compliance requires closing at $1.00 or more for at least ten consecutive business days
If not compliant, the company may qualify for a second 180 calendar day period, possibly through a reverse stock split; otherwise delisting proceedings could begin, with a right to appeal to a Nasdaq Hearings Panel
Shuttle Pharmaceuticals Holdings dismissed Forvis Mazars, LLP as its independent registered public accounting firm and engaged Bush & Associates CPA LLC on November 2, 2026. Bush & Associates will audit the fiscal year ending December 31, 2026, and review interim financial statements through September 30, 2027. The filing states no disagreements or reportable events with the former auditor.
Forvis Mazars dismissal was approved by the Audit Committee and full Board, effective after the Form 10-Q for the quarter ended September 30, 2026, as previously reported October 21, 2026.
Bush & Associates CPA LLC was engaged on November 2, 2026, under an engagement letter dated October 19, 2026.
Bush & Associates will audit fiscal 2026 and review interim quarters ending March 31, June 30 and September 30, 2027.
The company states there were no consultations with Bush & Associates on accounting matters and no disagreements or reportable events in fiscal 2024, fiscal 2025 or the interim period through November 2, 2026.
Mangoceuticals' sole Series B preferred holder approved terms for a new 8% Series D convertible cumulative preferred stock and an amendment to the Series B designation, which would allow the company to sell up to 1,000,000 shares at $10.00 each under Regulation A. The company said the instruments are not yet filed or effective and it may not proceed with the offering; the company also set its combined 2025 and 2026 annual meeting for December 30, 2026.
On November 2, 2026, the holder of all 50 outstanding Series B preferred shares approved the Series D terms and Series B amendment by written consent.
Proposed Series D offering: up to 1,000,000 shares at $10.00 per share under Regulation A; no sales will occur before the SEC qualifies the offering statement on Form 1-A.
Annual meeting set for December 30, 2026 in Dallas, Texas; record date is November 12, 2026.
Shareholder proposals and director nominations for the meeting are due by November 16, 2026.
Quoin Pharmaceuticals reported a net loss of $4.9 million for the quarter ended September 30, 2026, up from $3.9 million a year earlier, and a nine-month net loss of $15.2 million versus $11.5 million. The company said it had about $33.2 million in cash, cash equivalents and marketable securities at quarter end, and it highlighted positive interim Netherton Syndrome data and new regulatory designations. Shareholders see a wider loss alongside clinical and regulatory progress.
Q3 2026 net loss was approximately $4.9 million, compared with approximately $3.9 million in Q3 2025.
Nine-month 2026 net loss was approximately $15.2 million, compared with approximately $11.5 million for the same period in 2025.
Cash, cash equivalents and marketable securities were approximately $33.2 million as of September 30, 2026.
Up to $50.0 million private placement was announced August 28, 2026, with approximately $30.8 million in initial upfront funding.
Clean Energy Technologies, Inc. sold FuFront AI Pte. Ltd. a convertible promissory note with a principal amount of $2,000,000 for the same purchase price, with funding received and the transaction closed on November 4, 2026. The note carries 12% annual interest, matures October 3, 2027, and can convert into common stock at a discount to recent trading prices, which could dilute existing shareholders.
Principal of $2,000,000 at a purchase price of $2,000,000; closed November 4, 2026
Interest accrues at 12% per annum; note matures October 3, 2027
Convertible six months after issuance at 85% of the lowest traded price over the prior ten trading days
Conversion limited to 4.99% beneficial ownership, and to 2,432,004 aggregate shares absent Nasdaq Rule 5635(d) shareholder approval; holder deducts $1,750 per conversion for fees
RenX Enterprises exchanged $1,022,971.22 of principal and accrued interest under a February 12, 2026 senior convertible note for a new senior convertible note of $1,037,283.93 and a warrant to buy 644,944 shares, both issued November 2, 2026. The new note carries 10% interest and a 12-month maturity, and it can convert at $2.895 per share, with a possible alternate conversion price tied to a $0.534 floor once stockholders approve, which could add substantial share issuance for existing holders.
Exchanged $1,022,971.22 of the February 12, 2026 note for a new note of $1,037,283.93, equal to 110% of the prior note's outstanding principal.
New note bears 10% interest, matures in 12 months, and has an initial conversion price of $2.895 per share.
Alternate conversion, available after stockholder approval, is priced at the greater of a $0.534 floor and 92% of the lowest 10-day VWAP.
Warrant has a $2.67 exercise price and a six-year term; default interest rises to 18% per annum if an event of default occurs.
Greif reported fourth-quarter and fiscal 2026 results for the year ended September 30, 2026. Full-year net income rose to $261.5 million, and Adjusted EBITDA rose 11.7%, while fourth-quarter Adjusted EBITDA fell 3.1% to $163.0 million and Adjusted free cash flow of $279.3 million was below the company's most recent guidance range. The company also gave fiscal 2027 low-end guidance of $645 million Adjusted EBITDA and $290 million Adjusted free cash flow.
Fiscal 2026 net income was $261.5 million, or $4.54 per diluted Class A share, versus $31.6 million, or $0.55, a year earlier.
Fourth-quarter net loss narrowed to $6.5 million, or $0.11 per diluted Class A share, from a net loss of $24.3 million, or $0.42, a year earlier.
Company will close its Sweetwater paperboard mill in Austell, GA, and has achieved $105 million in cumulative run-rate cost savings, with a new target of $150 million by the end of fiscal 2027.
Fiscal 2027 low-end guidance: Adjusted EBITDA of $645 million and Adjusted free cash flow of $290 million.
Faraday Future issued one share of newly created Series A Preferred Stock to Executive Chairman Jiawei Wang for $100 on November 4, 2026. The share gives Wang 500,000,000 votes, but only on a proposed reverse stock split, so it strengthens the chairman's influence over that vote and changes the approval threshold for it.
One Series A Preferred share sold to Executive Chairman Jiawei Wang for $100.00, closed November 4, 2026.
The share carries 500,000,000 votes, limited to the Reverse Stock Split Proposal, and mirrors votes cast by common stockholders.
The share is redeemed for $100.00 automatically upon stockholder approval of the reverse split, or earlier at the Board's discretion.
Approval of the reverse split now requires a majority of combined voting power, including the Series A share.
BioVie Inc. agreed on November 3, 2026 to sell shares and pre-funded warrants in a registered direct offering and common warrants in a concurrent private placement, with aggregate gross proceeds of approximately $4.74 million before fees and expenses. The offering closed on November 5, 2026, and the company intends to use the net proceeds for working capital and general corporate purposes. The deal adds shares and dilutive warrants, and the company has agreed to restrictions on new share issuances.
Registered direct offering: 960,000 shares at $1.60 per share plus 2,002,500 pre-funded warrants at $1.5999 each
Concurrent private placement: 2,962,500 common warrants exercisable at $1.70 per share, starting six months after issuance
Placement agent A.G.P./Alliance Global Partners receives a cash fee of 7.0% of gross proceeds
Company and directors and officers agreed to issuance and sale restrictions for 60 days after the November 5, 2026 closing
Kontoor Brands completed the sale of its H.D. Lee Company subsidiary to ABG-Storm LLC, an affiliate of Authentic Brands Group, on November 2, 2026. The company received $750 million in cash at closing, subject to post-closing adjustments, plus up to $250 million in earnout payments tied to the Lee business's performance over five years. The filing says the company anticipates using $400 million for accelerated share repurchases and $50 million for open market repurchases.
Closing date: November 2, 2026; cash at closing of $750 million before post-closing adjustments
Pro forma estimate of cash received after adjustments: approximately $698.2 million
Earnout of up to $250 million over five years; estimated fair value at closing of $77.0 million
Planned use of proceeds: $400 million in accelerated share repurchases and $50 million in open market repurchases
Silo Pharma, Inc. entered into securities purchase agreements on November 5, 2026, and closed a private placement with accredited investors on November 6, 2026. The company expects net proceeds of approximately $815,000 for working capital and general corporate purposes, and it agreed to register the resale of the shares and warrant shares with the SEC, which adds potential future share supply for existing shareholders.
Sold 136,005 shares of common stock at $1.50 per share
Issued pre-funded warrants for up to 430,661 shares of common stock at $1.4999 per warrant
Expected net proceeds of approximately $815,000 after placement agent fees and offering expenses
Must file a resale registration statement within 30 days of the November 5, 2026 registration rights agreement, with effectiveness targeted within 60 days (90 days if the SEC conducts a full review)
Reed's, Inc. entered into a third amendment to its senior secured loan with Whitebox-affiliated lenders and Cantor Fitzgerald, adding new liquidity and equity-contribution conditions. The company must receive at least $2,500,000 in cash equity contributions by November 20, 2026, or an Event of Default will occur, and it must also pay a $25,000 extension fee by that date. The company said a delay in its previously announced private placement pushed the expected closing to on or before November 20, 2026, and it has so far received $7,500,000 in gross proceeds from that placement.
Minimum liquidity covenant of not less than $11,000,000 in Cash / Inventory / AR Liquidity, tested at any time and monthly after the Increased Liquidity Period
New Event of Default if at least $2,500,000 in cash equity contributions is not received by November 20, 2026
Non-refundable $25,000 extension fee due on or before November 20, 2026; nonpayment is an Event of Default
Private placement agreement dated October 28, 2026; $7,500,000 gross proceeds received to date
HeartSciences filed an 8-K with supplemental disclosures to its proxy statement for the proposed merger with Fortitude Mining Holdings, a subsidiary of Digital Currency Group. The company received seven demand letters from purported shareholders alleging the proxy omits material information, and says the claims are without merit but is voluntarily adding disclosures to avoid delays and litigation expense. The special meeting remains scheduled for November 19, 2026, so the disclosures do not change the vote timing.
Seven demand letters received from counsel to purported shareholders alleging proxy omissions.
Company denies the allegations and says disclosures are voluntary, made without admitting liability.
Supplemental disclosures include a January 6, 2026 letter of intent with Fortitude and an indicated equity value range for Fortitude of $206.0 million to $428.2 million.
Special Meeting to be held virtually on November 19, 2026, at 10:00 a.m. Eastern Time.
First Breach announced a supplier agreement giving it the ability to purchase up to 20 million primers per month, two additional ammunition inspection units, and a separate raw material supply agreement. The company says these steps support plans to scale ammunition production toward up to 20 million rounds per month and move toward 24-hour operations.
Primer agreement allows purchases of up to 20 million primers per month from a strategic supplier
Two additional ammunition inspection units added, supplementing equipment acquired earlier this year at the Hagerstown, Maryland facility
Separate raw material supply agreement announced; no financial terms, dollar values or contract durations were disclosed
Filing is a Regulation FD disclosure furnishing the November 3, 2026 press release; no financial results were reported
AST SpaceMobile said it will build its own 20-ton rocket, named Blacklift, to launch BlueBird satellites, starting in late 2028. It will pay about $800 million upfront for a license to make Firefly's Miranda and Vira engines and $500 million under a supply and services agreement. The filing gives no revenue, profit, or guidance figures, so its effect on financial results cannot be measured from this document.
Upfront license consideration of about $800 million: $400 million in cash plus 10 to 14 million Class A shares, based on a forward VWAP calculation
Supply and services agreement: $250 million for engines for the first three Blacklift launches and $250 million for engineering support over three years
Blacklift is designed for up to five BlueBird satellites per launch, with launches starting in late 2028
Company will host a Blacklift unveiling event on Thursday, November 12 in New York City
Avista furnished a November 2026 investor presentation that reaffirms its 2026 non-GAAP utility earnings guidance of $2.52 to $2.72 per diluted share. The presentation shows third-quarter GAAP net income of $49 million, up from $29 million a year earlier, and year-to-date GAAP net income of $176 million, up from $122 million.
Q3 2026 GAAP diluted EPS was $0.57 versus $0.36 in Q3 2025; non-GAAP utility EPS was $0.38 versus $0.37
Year-to-date 2026 GAAP diluted EPS was $2.11 versus $1.51; non-GAAP utility EPS was $1.76 versus $1.67
Washington general rate case decision is expected in mid-December; a $3.6 billion capital spend is planned for 2027-2031
Signed MOU seeks 10% ownership in the $6 billion North Plains Connector transmission line, with definitive agreements expected in 6-9 months
TuHURA Biosciences borrowed an additional $1.5 million on November 2, 2026, under the revolving credit facility from its April 21, 2026 Loan Agreement with Parkview Holdings One LLC. The facility has a maximum availability of $50 million and matures on April 21, 2031, and the company says it will use the funds for general corporate purposes.
Draw of $1,500,000 received and borrowed on November 2, 2026
Revolving facility with Parkview Holdings One LLC has maximum availability of $50 million
Facility matures April 21, 2031; the Loan Agreement was originally entered into April 21, 2026
Filing notes potential conflicts of interest because the lender is an affiliate of the company's largest stockholder
CPS Technologies reported fiscal third-quarter 2026 revenue of $8.9 million, up from $8.8 million a year earlier, with gross margin of 20.9% versus 17.1%. For the nine months, the company posted an operating loss of $423,415 compared with operating income of $542,659 a year earlier, and it signed a lease for an 80,000-square-foot facility in Attleboro, Massachusetts.
Q3 revenue of $8.9 million versus $8.8 million in the prior-year quarter
Q3 gross profit of $1.9 million, or 20.9% of revenue, versus 17.1% a year earlier
Q3 operating income of $357,747 versus $276,082; nine-month operating result was a loss of $423,415 versus income of $542,659
Company signed a long-term lease for an 80,000-square-foot facility in Attleboro, Massachusetts, about twice its current size
NorthWestern Energy filed a presentation for the EEI Financial Conference in Scottsdale, Arizona, November 8-10, 2026, in which executives will affirm the company's 2026 non-GAAP earnings guidance of $3.68 to $3.83 per diluted share. The filing reports no new financial results and no change to guidance, and the guidance excludes costs related to the pending merger with Black Hills Corp.
2026 non-GAAP EPS guidance of $3.68 to $3.83 per diluted share is affirmed, not changed
Presentation dated November 8, 2026, furnished as Exhibit 99.1 and not deemed filed under Section 18 of the Exchange Act
Presenters are CEO Brian Bird, CFO Crystal Lail, and Travis Meyer, director of corporate development and investor relations
The presentation cites a $3.21 billion five-year capital plan and a Montana final order on the Black Hills merger expected by November 12, 2026
Lazard filed a prospectus supplement covering the possible resale of up to 9,416,817 common shares issued to sellers in its previously announced acquisition of Campbell Lutyens Holdings Limited. The filing is administrative and sets up potential sales of these shares by the selling stockholders, which could add to the number of shares available in the market.
Prospectus supplement under Rule 424(b) filed November 6, 2026, covering up to 9,416,817 shares of common stock
Sullivan & Cromwell LLP opinion on share validity filed as Exhibit 5.1
Data Storage Corporation said director Harold J. Schwartz resigned from its Board of Directors, effective immediately, after notifying the Board on November 4, 2026. The company said the resignation was not due to any disagreement over its operations, policies or practices, and that Mr. Schwartz did not serve on any Board committee.
Harold J. Schwartz resigned as a Board member, effective immediately
Notice to the Board was given on November 4, 2026; the 8-K was dated November 6, 2026
Company states no disagreement with management on operations, policies or practices
Mr. Schwartz previously served as an officer of former subsidiary CloudFirst Technologies Corporation and sat on no Board committee
Santander Holdings USA, Inc. (SHUSA) said it will redeem all 6,000 outstanding shares of its Series H Preferred Stock and the corresponding 6,000,000 depositary shares on December 15, 2026. Depositary shares will be redeemed at $25.00 each, and the redemption price excludes the regular quarterly dividend, which is payable separately on the same date to holders of record on November 30, 2026.
Redemption date: December 15, 2026, covering 6,000 preferred shares and 6,000,000 depositary shares.
Redemption price: $25.00 per depositary share, not including the declared quarterly dividend.
Quarterly dividend: $0.328125 per depositary share, payable December 15, 2026 to holders of record as of November 30, 2026.
Redemption agent: Broadridge Corporate Issuer Solutions, LLC; shares are held through DTC.
Hyster-Yale reported third-quarter 2026 revenue of $827 million, up from $813 million in the second quarter, and narrowed its operating loss to $9 million from $18 million. The company said it expects Q4 2026 revenue to grow sequentially on higher shipments, but tariff-related costs remain elevated and the company plans new cost-reduction programs targeting at least $100 million at maturity in 2029.
Q3 2026 revenue was $827 million versus $813 million in Q2 2026; net loss narrowed to $15 million from $32 million
Operating loss was $9 million in Q3 2026 versus an operating profit of $2.3 million in Q3 2025
Company expects Q4 2026 bookings to exceed Q4 2025 and Q3 2026, with sequential revenue growth
New programs targeting at least $100 million of cost reductions and mitigations at maturity, expected in 2029
Gogo and its subsidiary GIH signed a third amendment to their 2021 credit agreement, converting $544.4 million of term loans into new 2026 Extended Term Loans that mature October 31, 2030. The amendment requires $75 million of prepayments through December 31, 2027 and sets a higher interest margin of 5.75% over SOFR, so shareholders gain more time on debt maturities but pay more in interest and face required debt repayments.
2026 Extended Term Loans of $544.4 million mature October 31, 2030; Initial Term Loans of $33.4 million mature April 30, 2028
Required prepayments: $25.0 million on the November 6, 2026 closing date, $30.0 million by December 31, 2026, and $20.0 million by December 31, 2027
Interest at SOFR plus 5.75% or an alternate base rate plus 4.75%; quarterly amortization begins March 31, 2027
Amendment adds certain foreign subsidiaries as guarantors and grants additional collateral on a pari passu basis with the HPS Credit Agreement
BCP Investment Corporation postponed the release of its third quarter 2026 financial results and the related conference call, which were originally scheduled for November 5 and November 6, 2026. The company said the delay gives management more time to finalize financial disclosures, regulatory filings and structural terms tied to a potential strategic initiative, and that there is no assurance this will lead to a definitive agreement or transaction.
Q3 2026 results release and conference call postponed from November 5 and November 6, 2026
Delay tied to finalizing disclosures, regulatory filings and structural terms of a potential strategic initiative
Company states the delay is not related to any accounting, financial or regulatory matters
New call date and dial-in details to be issued by separate press release in the coming days
Health In Tech, Inc. issued a second promissory note to investor YA II PN, Ltd. on November 2, 2026, with a principal amount of $3.0 million, which provided gross proceeds of $2.85 million after a 5% purchase price discount. The notes are convertible into Class A common stock at a fixed price of $1.5735 per share and can be converted into shares that could dilute existing holders, with an Exchange Cap of 13,100,378 shares that the company is seeking stockholder approval to exceed at its November 10, 2026 annual meeting.
Second promissory note issued November 2, 2026: $3.0 million principal, $2.85 million gross proceeds after 5% discount
Notes mature February 18, 2028, bear 8.75% annual interest (18% after certain defaults), and carry a 4% payment premium unless paid via stock sale proceeds
Conversion price fixed at $1.5735 per share with a floor price of $0.204; Exchange Cap is 13,100,378 shares, about 19.99% of outstanding Class A and Class B common stock
Company seeks stockholder approval to issue shares above the Exchange Cap at its annual meeting on November 10, 2026
FB Bancorp reported third-quarter 2026 net income of $466 thousand, down from $1.1 million a year earlier, as non-interest expenses rose and net interest margin fell to 4.30% from 4.65%. Nine-month net income was $515 thousand versus $2.7 million, including a $1.1 million loss from discontinued mortgage banking operations. Shareholders face lower earnings and a commercial loan of approximately $19.8 million now classified as substandard.
Q3 2026 net income was $466 thousand versus $1.1 million in Q3 2025; continuing operations EPS was $0.03 versus $0.06.
Nine-month 2026 net income was $515 thousand, including a $1.1 million loss from discontinued operations, versus $2.7 million a year earlier.
Non-interest expenses rose $390 thousand, or 3.33%, in Q3 2026 year over year, with $686 thousand of stock-based compensation.
A commercial loan with a principal balance of approximately $19.8 million was classified substandard after two co-borrower entities filed for Chapter 11 in June 2026; no specific allowance was recorded.
RPM International's Chairman and CEO Frank C. Sullivan announced on November 6, 2026 that he plans to retire within the next twelve to eighteen months. He will remain in his role until a successor is appointed and is expected to then stay on as Chair of the Board, as the company runs a succession planning process with its Board.
Frank C. Sullivan plans to retire in the next twelve to eighteen months, per the November 6, 2026 filing.
Sullivan has served nearly 25 years as Chairman and CEO and more than 40 years with the company.
He will remain CEO until his successor is appointed and is expected to stay on as Board Chair afterward.
Delta Air Lines completed a public offering of $500 million in 5.500% notes maturing November 6, 2029, on November 6, 2026. The company said it will use part of the proceeds to repay about $391 million of Payroll Support Program loan borrowings, about $70 million of aircraft-secured equipment notes, and, with cash on hand, about $39 million of pass through certificates, with any remainder for general corporate purposes. The filing adds new unsecured debt to the balance sheet while reducing several existing obligations.
Notes: $500 million aggregate principal, 5.500% coupon, maturing November 6, 2029
Interest paid semi-annually on May 6 and November 6, starting May 6, 2027
Proceeds to repay about $391 million Payroll Support Program loan, about $70 million equipment notes, and about $39 million pass through certificates
American Healthcare REIT entered into a new at-the-market equity sales agreement allowing it to sell up to $1.75 billion of common stock through a group of sales agents and forward purchasers. The company terminated its prior program, which had about $170 million left unsold, and says it will use any net proceeds for general corporate purposes, which may include future investments.
Agreement allows sales of common stock with an aggregate gross sales price of up to $1,750,000,000, replacing the prior program dated February 27, 2026.
About $170,134,000 remained unsold under the prior sales agreement when it was terminated.
Agents may receive a commission of up to 2.0% of gross sales price; shares are sold under a shelf registration statement on Form S-3 dated August 12, 2024.
Proceeds would go to the Operating Partnership for general corporate purposes, which may include potential future investments.
Victory Capital filed an 8-K with supplemental disclosures to its proxy statement for the planned acquisition of First Eagle, which it says it made voluntarily to reduce the risk of litigation delaying the deal. Two stockholder lawsuits and a number of demand letters allege the proxy statement was materially incomplete and misleading, and Victory says those claims are without merit. The company states the supplemental disclosures do not change the consideration or the timing of the November 17, 2026 special meeting.
Base purchase price for First Eagle is $7.03 billion, subject to adjustment, including a reduction for First Eagle's funded debt and other debt-like items.
Share consideration is valued at $2 billion based on $116.26 per share and represents 4.9% of Victory's outstanding common stock after issuance.
Two complaints were filed in New York Supreme Court on October 27 and October 28, 2026, and plaintiffs seek to enjoin the deal or seek rescission or damages.
The special meeting of Victory stockholders is scheduled for November 17, 2026, and the board still recommends voting FOR the proposals.
Silgan signed a consent to its credit agreement with Wells Fargo as administrative agent, letting lenders designate a new subsidiary, Silgan Metal Packaging LLC, as an unrestricted subsidiary. The change supports the planned contribution of several container and closure businesses to that entity under the October 17, 2026 Transaction Agreement. The filing gives no financial results or deal value, so the near-term effect on shareholders is not quantified here.
Consent to Amended and Restated Credit Agreement dated November 6, 2026, with Wells Fargo Bank, National Association, as Administrative Agent
Silgan Metal Packaging LLC (MetalCo) to be designated an Unrestricted Subsidiary, releasing it as a guarantor under the credit agreement
Business Contribution tied to the Transaction Agreement dated October 17, 2026 with A-VL Holdco, LP
If the MetalCo Transactions do not close, MetalCo and its subsidiaries will cease to be Unrestricted Subsidiaries
Profusa, Inc. entered into Amendment No. 4 to its Note Modification and Conversion Agreement with holder NorthView Sponsor I LLC on November 5, 2026. The amendment sets a $0.20 floor on the conversion price for the note, which has an original principal amount of up to $2,500,000. The change could result in a larger number of shares being issued to the holder on conversion, which may dilute existing shareholders.
Amendment No. 4 dated November 5, 2026 sets conversion price at the greater of $0.20 Floor Price or the prior trading day's Nasdaq closing price
Conversion shares are calculated as principal multiplied by 122%, divided by the conversion price, unchanged by the amendment
The prior Amendment No. 3 of August 12, 2026 set the conversion price at the greater of $4.28 or the prior trading day's closing price
Original note principal amount of up to $2,500,000, with the agreement first entered April 24, 2026
Hyatt Hotels filed a Regulation FD disclosure on lock-up restrictions covering its Class A and Class B shares. Based on current agreements, 14,685,256 restricted shares held by Pritzker family stockholders will be available for public sale from November 5, 2026 through November 4, 2027, which could add supply to the stock market.
14,685,256 restricted shares held by Pritzker family stockholders may be sold from November 5, 2026 to November 4, 2027
2,270,395 additional restricted Class B shares held by other 2007 Stockholders' Agreement parties are available for sale at any time, subject to Company rights of first refusal
An additional 2,678 restricted shares are not subject to lock-up restrictions
Nexentis Technologies Inc. effected a 1-for-5 reverse stock split of its common stock, under authority approved by stockholders on April 30, 2026. The split took effect at 4:15 p.m. Eastern Time on November 6, 2026, and the stock will trade on a split-adjusted basis on the Nasdaq Capital Market from November 9, 2026, under the existing symbol NXTS. The company said the split is intended to raise the per-share price and bid price to regain compliance with Nasdaq continued listing requirements.
Every 5 outstanding shares converted into 1 share; per-share exercise prices and option and warrant share counts adjusted proportionately
Outstanding shares to fall from approximately 2.9 million to approximately 600 thousand, per the press release
Trading begins on a split-adjusted basis November 9, 2026, under new CUSIP 80512Q709
Authorized common stock unchanged at 495,000,000 shares; fractional shares rounded up to the next whole share
Curis received a Nasdaq letter on November 2, 2026 stating its stock closed below the $1.00 minimum bid price for 30 consecutive business days, and it is not eligible for a standard compliance period because of its recent reverse stock split. The company intends to request a new hearing, which would stay further delisting actions, but says there is no assurance the appeal will succeed or that its shares will remain listed on Nasdaq.
Nasdaq letter dated November 2, 2026 cites bid price below $1.00 for 30 consecutive business days under Rule 5550(a)(2)
Company effected a 1-for-20 reverse stock split on July 6, 2026, which makes it ineligible for a compliance period
Following a Nasdaq Hearings Panel decision dated July 24, 2026, Curis is subject to a Discretionary Panel Monitor for one year
Company intends to request a new hearing; no assurance of success or continued Nasdaq listing
Jaguar Health held a special meeting of stockholders on November 6, 2026, and all six proposals were approved. The approvals cover a reverse stock split at a ratio between 1-for-2 and 1-for-150, to be set by the board, and a reduction in the floor price of an equity line agreement with C/M Capital from $16.50 to $1.10 per share. The reverse split was approved under the Votes Cast Standard but not under the Majority of Outstanding Standard, as the filing notes.
Special meeting held November 6, 2026; 3,383,169 of 7,802,102 shares of common stock outstanding as of the September 15, 2026 record date were represented.
Reverse stock split approved at a ratio of not less than 1-for-2 and not greater than 1-for-150; the board will set the exact ratio and announce it within one year.
Reverse split vote was 3,551,428 for and 222,394 against, but not approved under the Majority of Outstanding Standard.
ELOC Agreement floor price cut from $16.50 to $1.10 per share; 2,400,107 votes for and 158,386 against.
D. Boral Acquisition I Corp., a British Virgin Islands blank-check company, disclosed that director Benjamin Piggott resigned from its board on September 23, 2026, saying the decision was not related to any disagreement with the company. The board appointed Kevin McGurn and Luisa Ingargiola to its Audit and Compensation Committees, with McGurn also named Compensation Committee chair. The changes are board administration and do not include any financial or operational figures.
Benjamin Piggott resigned from the board, effective with notice to the board on September 23, 2026
Kevin McGurn appointed to the Audit Committee and named Compensation Committee chair, effective September 23, 2026
Luisa Ingargiola appointed to the Compensation Committee, effective September 23, 2026
McGurn reassigned from Class I to Class II director; his term expires at the second annual shareholder meeting
Fractyl Health's board increased its size from nine to ten and appointed Michael Wartell as an independent Class III director effective November 2, 2026. Wartell will receive $40,000 per month in cash compensation under a director agreement, with a minimum of three months guaranteed unless he resigns.
Michael Wartell appointed effective November 2, 2026; term expires at the 2027 annual meeting
Cash compensation of $40,000 per month, payable monthly in advance, with a three-month minimum unless he resigns
Additional $3,000 for each day Board commitments exceed four hours outside normal Board duties
Wartell has not been appointed to any Board committee and will not join the Non-Employee Director Compensation Policy
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.